Inhibition of phospholipase A2 by gabexate mesilate, camostate and aprotinine.
Gabexate mesilate (FOY, ethyl-p-[6-guanidino-hexanoyloxy]-benzoate-methanesulfonate), camostate (N,N-dimethyl-carbamoylmethyl-4-[4-guanidinobenzoyloxy]-phenylacetate), methanesulfonate (FOYPAN) and aprotinine (Trasylol) were tested for possible inhibition of phospholipase A2. Gabexate mesilate at a concentration of 5 x 10(-4) mol/l and camostate at a concentration of 10(-3) mol/l caused a 50% reduction in enzyme activity. There was no inhibition by aprotinine at clinical doses; 40 million KIU/l were necessary to reduce phospholipase A2 activity by 20%.
D000818:Animals; D007611:Aprotinin / Q000494:pharmacology*; D004952:Esters; D016670:Gabexate; D006146:Guanidines / Q000494:pharmacology*; D007700:Kinetics; D010179:Pancreas / Q000201:enzymology; D010740:Phospholipases / Q000037:antagonists & inhibitors*; D010741:Phospholipases A / Q000037:antagonists & inhibitors*; D054467:Phospholipases A2; D011480:Protease Inhibitors / Q000494:pharmacology*; D013552:Swine
D004952:Esters; D006146:Guanidines; D011480:Protease Inhibitors; C034532:camostat; D016670:Gabexate; D007611:Aprotinin; D010740:Phospholipases; D010741:Phospholipases A; D054467:Phospholipases A2